Pipeline

The MMRC and its team of Principal Investigators are committed to excellence in multiple myeloma research. With lives on the line, everything we do focuses on accelerating discovery and rapidly advancing medicine.

The MMRC has conducted more than 75 Phase I and II trials enrolling more than 1,500 patients to-date, providing invaluable insight into the successful conduct of multiple myeloma clinical trials.

The major differentiating factors in working with MMRC for the conduct of Phase I and II trials in multiple myeloma are:

  • Streamlined communication—single point of contact who can leverage MMRC’s extensive MM Phase I/II clinical trial experience
  • MMRC is a recognized MM center of excellence for Phase I/II trials with focus on quality of trial conduct and data integrity, including renowned MM Key Opinion Leaders (KOL)
  • Leveraging a patient-driven collaborative research model that demonstrates faster trial starts and enrollment for MM Phase I/II trials

Current MMRC Trials

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

TRIAL ON HOLD

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma (enrolling at Yale, New Haven, CT only)

ENROLL NOW

Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma

ENROLLMENT CLOSED

A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM)

TRIAL ON HOLD

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

ENROLLMENT CLOSED

Phase 2b Open-Label Single-Arm Study of Selinexor & Dexamethasone in Patients Exposed to Bortezomib, Carfilzomib, Lenalidomide and Pomalidomide

ENROLL NOW

Study of Bortezomib, Lenalidomide, Dexamethasone & Elotuzumab in Newly Diagnosed MM

ENROLLMENT CLOSED

“Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

ENROLL NOW

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

ENROLL NOW

Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma

ENROLLMENT CLOSED

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

ENROLLMENT CLOSED

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

ENROLLMENT CLOSED

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

ENROLLMENT TEMPORARILY CLOSED

Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma

ENROLL NOW

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

ENROLLMENT CLOSED

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

ENROLLMENT CLOSED

Study of the Bruton’s Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

ENROLLMENT CLOSED

SAR650984, Lenalidomide, and Dexamethasone in Combination in RRMM Patients

ENROLLMENT CLOSED